Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.

Jagasia, Madan; Zeiser, Robert; Arbushites, Michael; Delaite, Patricia; Gadbaw, Brian; Bubnoff, Nikolas von

Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials.

Jagasia, Madan; Zeiser, Robert; Arbushites, Michael; Delaite, Patricia; Gadbaw, Brian; Bubnoff, Nikolas von.

Afiliación

Jagasia M; Vanderbilt-Ingram Cancer Center, 1301 Medical Center Dr #1710, Nashville, TN, USA 37232.
Zeiser R; Department of Hematology, Oncology & Stem Cell Transplantation, University Hospital Freiburg, Hugstetter Str. 55, 79106 Freiburg im Breisgau, Germany.
Arbushites M; Incyte Corporation, 1801 Augustine Cut-off, Wilmington, DE, USA 19803.
Delaite P; Incyte Corporation, 1801 Augustine Cut-off, Wilmington, DE, USA 19803.
Gadbaw B; Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, USA 07936.
Bubnoff NV; Department of Hematology, Oncology & Stem Cell Transplantation, University Hospital Freiburg, Hugstetter Str. 55, 79106 Freiburg im Breisgau, Germany.

Immunotherapy ; 10(5): 391-402, 2018 04.

Article en En | MEDLINE | ID: mdl-29316837

Asunto(s)

Corticoesteroides; Enfermedad Injerto contra Huésped/tratamiento farmacológico; Pirazoles/uso terapéutico; Humanos; Nitrilos; Estudios Prospectivos; Pirimidinas; Resultado del Tratamiento

Palabras clave

JAK; allogeneic stem cell transplant; refractory graft-versus-host disease

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Pirazoles / Corticoesteroides / Enfermedad Injerto contra Huésped Tipo de estudio: Clinical_trials / Observational_studies Límite: Humans Idioma: En Revista: Immunotherapy Asunto de la revista: ALERGIA E IMUNOLOGIA / TERAPEUTICA Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google